Clinical presentations of atherothrombotic vascular disease, such as acute coronary
syndromes, ischemic stroke or transient ischemic attack, and symptomatic peripheral arterial …

Despite the proven efficacy of dual antiplatelet therapy with aspirin and one of the first-
generation P2Y12 antagonists (clopidogrel, prasugrel) in patients with atherothrombotic …

Coronary atherothrombotic disease, including chronic stable angina and acute coronary
syndromes (ACS), is associated with significant global burden. The acute clinical …

Antiplatelet drugs are important components in the management of atherothrombotic
vascular disease. However, several limitations restrict the safety and efficacy of current …

Atherosclerosis is a diffuse, systemic disorder of the large and medium-sized arterial
vessels, affecting the coronary, cerebral and peripheral circulation. Chronic inflammatory …

Platelets are now regarded as playing a dominant role in cardiovascular medicine since our
recent understanding of acute coronary syndrome as an atherothrombotic process. This …

Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or
those undergoing percutaneous coronary intervention (PCI) are essentially platelet‐driven …

Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease,
cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of …

Arterial thrombosis frequently leads to death or disability from stroke, peripheral arterial
disease, or myocardial infarction (MI). Treating the underlying causes of these diseases is …

Antiplatelet therapies are an essential tool to reduce the risk of developing clinically
apparent atherothrombotic disease and are a mainstay in the therapy of patients who have …